Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003074413 | SCV003454743 | uncertain significance | Gorlin syndrome | 2022-06-09 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr674Ilefs*26) in the PTCH2 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in PTCH2 cause disease. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals affected with PTCH2-related conditions. This variant is present in population databases (rs769826884, gnomAD 0.01%). |
Fulgent Genetics, |
RCV005019619 | SCV005650030 | uncertain significance | Basal cell carcinoma, susceptibility to, 1; Medulloblastoma | 2024-06-05 | criteria provided, single submitter | clinical testing |